Effect of melatonin on depressive symptoms and anxiety in patients undergoing breast cancer surgery: a randomized, double-blind, placebo-controlled trial
| Autor: | Ida Hageman, Ismail Gögenur, Lars S. Rasmussen, Melissa Voigt Hansen, Jacob Rosenberg, Susanne Bokmand, Lærke Toftegård Andersen, Michael Tvilling Madsen |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Sleep Wake Disorders Cancer Research medicine.medical_specialty Breast surgery medicine.medical_treatment Major Depression Inventory Placebo-controlled study Breast Neoplasms Anxiety Placebo law.invention Melatonin Placebos Breast cancer Randomized controlled trial Double-Blind Method law Surveys and Questionnaires Medicine Humans Fatigue Mastectomy Aged business.industry Depression Central Nervous System Depressants Middle Aged medicine.disease Antidepressive Agents Surgery Treatment Outcome Oncology Female medicine.symptom business medicine.drug |
| Zdroj: | Breast cancer research and treatment. 145(3) |
| ISSN: | 1573-7217 |
| Popis: | Depression, anxiety and sleep disturbances are known problems in patients with breast cancer. The effect of melatonin as an antidepressant in humans with cancer has not been investigated. We investigated whether melatonin could lower the risk of depressive symptoms in women with breast cancer in a three-month period after surgery and assessed the effect of melatonin on subjective parameters: anxiety, sleep, general well-being, fatigue, pain and sleepiness. Randomized, double-blind, placebo-controlled trial undertaken from July 2011 to December 2012 at a department of breast surgery in Copenhagen, Denmark. Women, 30-75 years, undergoing surgery for breast cancer and without signs of depression on Major Depression Inventory (MDI) were included 1 week before surgery and received 6 mg oral melatonin or placebo for 3 months. The primary outcome was the incidence of depressive symptoms measured by MDI. The secondary outcomes were area under the curve (AUC) for the subjective parameters. 54 patients were randomized to melatonin (n = 28) or placebo (n = 26) and 11 withdrew from the study (10 placebo group and 1 melatonin group, P = 0.002). The risk of developing depressive symptoms was significantly lower with melatonin than with placebo (3 [11 %] of 27 vs. 9 [45 %] of 20; relative risk 0.25 [95 % CI 0.077-0.80]), giving a NNT of 3.0 [95 % CI 1.7-11.0]. No significant differences were found between AUC for the subjective parameters. No differences in side effects were found (P = 0.78). Melatonin significantly reduced the risk of depressive symptoms in women with breast cancer during a three-month period after surgery. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink